Immunovant, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2025 | — | $707.4M | $714.0M |
| Jun 2025 | — | $608.5M | $598.9M |
| Sep 2025 | — | $519.7M | $521.9M |
| Dec 2025 | — | $986.1M | $994.5M |
| Mar 2026 | — | $852.6M | $902.1M |
| Jun 2026 | — | $735.4M | $797.8M |
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2025 | — | $707.4M | $714.0M |
| Jun 2025 | — | $608.5M | $598.9M |
| Sep 2025 | — | $519.7M | $521.9M |
| Dec 2025 | — | $986.1M | $994.5M |
| Mar 2026 | — | $852.6M | $902.1M |
| Jun 2026 | — | $735.4M | $797.8M |